Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Noiiglutide - Jiangsu Hansoh Pharmaceutical

Next Previous
Drug Profile

Noiiglutide - Jiangsu Hansoh Pharmaceutical

Alternative Names: HS 20004; HTI-2088; Noiigliutide-injection; SHR-20004

Latest Information Update: 11 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hansoh Pharmaceutical
  • Developer Hengrui Therapeutics; Jiangsu Hansoh Pharmaceutical; Jiangsu Hengrui Medicine Co.
  • Class Antihyperglycaemics; Glucagon-like peptides; Obesity therapies; Peptides
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus
  • Phase II Obesity

Most Recent Events

  • 25 Oct 2024 Phase-III clinical trials in Type 2 diabetes mellitus in China (SC) (NCT06649773)
  • 20 Oct 2024 Jiangsu HengRui Medicine plans a phase III trial for Type 2 diabetes mellitus (Combination therapy) in China (SC, Injection) in October 2024 (NCT06649773)
  • 26 Dec 2023 Jiangsu HengRui Medicine initiates enrolment in a phase I trial in Type 2 diabetes mellitus (In volunteers) in China (SC) (NCT06137469)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top